Advanced searches left 3/3

Adjunct Treatment - Europe PMC

Summarized by Plex Scholar
Last Updated: 20 September 2022

* If you want to update the article please login/register

Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against Mycobacterium avium infection but is ineffective as an adjunct to antibiotic treatment in chronic disease.

We compared the immunogenicities, protective efficacies, and immune correlates of Mav-derived culture filtrate antigens as a vaccine antigen with glucopyranosyl lipid. Interestingly, CFA+GLA-SE/CDG immunization induced more CFA-specific Th1/Th17 responses in both the lung and spleen than among the test groups. According to vaccination reasons, strong Mav CFA-specific Th1/Th17 responses are vital for preventative care against Mav infection, but they may be ineffective or even harmful in an established and chronic disease epidemic, which can result in chronic disease.

Source link: https://europepmc.org/article/MED/35499090


Evaluation of the effect of T-Scan™ as an adjunct to stabilization splint in the treatment of temporomandibular joint disorders.

Objective: To determine the success of the stabilization splint and the T-Scan2122 III system in the treatment of temporomandibular joint disorder with myofascial pain, see Figure 1. After occlusal adjustment under T-Scanu2122's direction, the occlusal contacts of patients in the SS plus T-ScanU2122 group's lower Occlusal Time, Disocclusion Time, and Asymmetry Index of Occlusal Force decreased. The TMD symptoms were alleviated more in the SS+ T-Scan2122 group, with improved ratings for MCO and MFIQ.

Source link: https://europepmc.org/article/MED/36094222


Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis.

b) xenoble, irreversible monoamine oxidase type B inhibitor used as monotherapy in early Parkinson's disease and as an adjunct therapy to levodopa in Parkinson's disease with motor disturbances. Objectives This meta-analysis aimed to publish new data on the efficacy of motor and non-motor disorders, as well as the safety of rasagiline/levodopa versus levodopa in Parkinson's disease patients with motor dysfunctions. Methods The study was conducted in PubMed, Cochrane Library, EMBASE, Web of Science, and Google Scholar to find randomized controlled trials comparing rasagiline/levopa to placebo/levodopa in Parkinson's disease patients with motor fluctuations. Conclusions and Conclusions This meta-analysis further established the effectiveness of rasagiline/levodopa in improving motor and nonmotor symptoms of Parkinson's disease in Parkinson's disease, with a similar safety profile to levodopa in Parkinson's disease with motor fluctuations.

Source link: https://europepmc.org/article/MED/36081594

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions